1. HeartSciences announces commercial release of MyoVista Insights 1.1 for ECG management. 2. The update enhances clinical interpretation and workflow efficiency across ECG devices. 3. Early adopters validate the platform's effectiveness; key customer deployments expected soon. 4. MyoVista Insights supports AI algorithms, improving decision-making and reducing costs. 5. The platform aims to provide patient-centered cardiac care through streamlined processes.
FAQ
Why Bullish?
The release of MyoVista Insights 1.1 demonstrates technological advancement and competitive edge, likely increasing investor interest. Historical market reactions to innovative healthcare solutions support this stance.
How important is it?
The significant product enhancement positions HSCS favorably in the market, potentially driving stock value up.
Why Long Term?
Continuous updates and customer engagements indicate sustained growth potential, similar to past successful product launches in healthcare IT sectors.
HeartSciences Launches MyoVista Insights™ Version 1.1, Enhancing ECG Management
Southlake, TX, Dec. 11, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS), a pioneering healthcare information technology company, has announced the commercial launch of MyoVista Insights™ version 1.1. This significant update includes enhanced clinical interpretation capabilities, improved workflow efficiency, and expanded interoperability across various ECG devices, positioning HeartSciences at the forefront of ECG management technology.
Overview of MyoVista Insights™ Version 1.1
MyoVista Insights™ is a next-generation ECG management system designed to facilitate the integration of artificial intelligence (AI) into clinical practice. According to Andrew Simpson, CEO of HeartSciences, this platform is engineered to deliver substantial clinical, operational, and data-security advantages to healthcare systems. “Since its launch in May 2025, we have received strong validation from early adopters and are engaged in commercial discussions with several leading healthcare institutions,” said Simpson. The company anticipates announcing key customer deployments soon.
Key Features and Improvements
The latest version of MyoVista Insights™ provides healthcare professionals with:
- Intuitive User Interface: An enhanced, user-friendly platform for improved cardiac care.
- Streamlined Workflows: Simplified processes that allow clinicians to quickly interpret ECG results.
- Device Agnosticism: Compatibility with a broad array of ECG devices and file formats.
- Advanced AI Algorithms: Hosting models from various partners to improve clinical decision-making and operational efficiency.
Clinical and Operational Benefits
The upgraded features of MyoVista Insights™ not only enhance clinical data interpretation but also streamline the workflow for healthcare providers. By optimizing study organization and incorporating sophisticated waveform tools, this platform empowers care teams to focus on achieving better patient outcomes. HeartSciences aims to provide timely, precise, and patient-centered cardiac care as part of its ongoing commitment to advancing healthcare technology.
About HeartSciences
HeartSciences Inc. is a healthcare information technology company focused on revolutionizing the use of ECG/EKGs through AI integration. The company’s MyoVista Insights platform embodies a device-agnostic approach to improve ECG management, while the MyoVista wavECG device offers tailored on-device solutions. For further information, visit HeartSciences' website.
Safe Harbor Statement
This announcement contains forward-looking statements regarding HeartSciences' future financial and operational performance, made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties, and investors should not place undue reliance on them. Potential risks include factors discussed in HeartSciences' Annual Report on Form 10-K and Quarterly Reports filed with the U.S. Securities and Exchange Commission (SEC).
Investor Relations and Media Contact
For investor inquiries, please contact:
Mark Komonoski
Integrous Communications
Phone: 877 255 8483
Email: mkomonoski@integcom.us
For media inquiries, please reach out to:
Gene Gephart
HeartSciences
Phone: +1 682 244 2578 Ext. 2024
Email: info@heartsciences.com